AP3360A - Pyrazole compounds as CRTH2 antagonists - Google Patents

Pyrazole compounds as CRTH2 antagonists

Info

Publication number
AP3360A
AP3360A AP2012006313A AP2012006313A AP3360A AP 3360 A AP3360 A AP 3360A AP 2012006313 A AP2012006313 A AP 2012006313A AP 2012006313 A AP2012006313 A AP 2012006313A AP 3360 A AP3360 A AP 3360A
Authority
AP
ARIPO
Prior art keywords
pyrazole compounds
crth2 antagonists
crth2
antagonists
pyrazole
Prior art date
Application number
AP2012006313A
Other languages
English (en)
Other versions
AP2012006313A0 (en
Inventor
Thorsten Oost
Wolfgang Rist
Dominic Martyres
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42112128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3360(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2012006313A0 publication Critical patent/AP2012006313A0/xx
Application granted granted Critical
Publication of AP3360A publication Critical patent/AP3360A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
AP2012006313A 2010-01-27 2011-01-24 Pyrazole compounds as CRTH2 antagonists AP3360A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151785 2010-01-27
PCT/EP2011/050910 WO2011092140A1 (fr) 2010-01-27 2011-01-24 Composés pyrazole comme antagonistes du crth2

Publications (2)

Publication Number Publication Date
AP2012006313A0 AP2012006313A0 (en) 2012-06-30
AP3360A true AP3360A (en) 2015-07-31

Family

ID=42112128

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006313A AP3360A (en) 2010-01-27 2011-01-24 Pyrazole compounds as CRTH2 antagonists

Country Status (37)

Country Link
US (1) US8791272B2 (fr)
EP (1) EP2528901B9 (fr)
JP (1) JP5658284B2 (fr)
KR (2) KR101812000B1 (fr)
CN (3) CN108383789A (fr)
AP (1) AP3360A (fr)
AR (1) AR080032A1 (fr)
AU (1) AU2011209286B2 (fr)
BR (1) BR112012018695A2 (fr)
CA (1) CA2788224C (fr)
CL (1) CL2012001836A1 (fr)
CO (1) CO6511272A2 (fr)
CY (1) CY1116641T1 (fr)
DK (1) DK2528901T3 (fr)
EA (1) EA022280B1 (fr)
ES (1) ES2545865T3 (fr)
GE (1) GEP20146177B (fr)
HK (1) HK1176062A1 (fr)
HR (1) HRP20150898T1 (fr)
HU (1) HUE025318T2 (fr)
IL (1) IL220208A (fr)
MA (1) MA33937B1 (fr)
MX (1) MX353000B (fr)
MY (1) MY160036A (fr)
NZ (1) NZ600637A (fr)
PE (1) PE20121519A1 (fr)
PL (1) PL2528901T3 (fr)
PT (1) PT2528901E (fr)
RS (1) RS54176B1 (fr)
SG (1) SG182684A1 (fr)
SI (1) SI2528901T1 (fr)
TN (1) TN2012000371A1 (fr)
TW (1) TWI499416B (fr)
UA (1) UA110025C2 (fr)
UY (1) UY33201A (fr)
WO (1) WO2011092140A1 (fr)
ZA (1) ZA201204335B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012018695A2 (pt) 2010-01-27 2016-04-12 Boehringer Ingelheim Int compostos pirazol como antagonistas crth2
EP2643303A1 (fr) 2010-11-24 2013-10-02 Allergan, Inc. Modulateurs de récepteurs de la s1p
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
CN103113303A (zh) * 2011-11-16 2013-05-22 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的氮杂环化合物
EP2781508B9 (fr) * 2011-11-17 2019-08-21 KBP Biosciences Co., Ltd. Composés cycliques condensés contenant de l'azote pour utilisation en tant qu'antagonistes du crth2
CA2862263C (fr) * 2011-12-27 2016-09-06 Allergan, Inc. Composes agissant au niveau de multiples recepteurs de prostaglandine generant une reponse anti-inflammatoire generale
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
WO2014079805A1 (fr) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Composés de pyrazole pour traiter l'alopécie
DK2970138T3 (en) 2013-03-13 2019-03-25 Canadian Blood Services PYRAZOLD DERIVATIVES AND THEIR USE THEREOF
CN103265535B (zh) * 2013-05-14 2015-06-17 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
CN103265537B (zh) * 2013-05-14 2015-05-27 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
TW202413336A (zh) 2018-03-08 2024-04-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CR20210605A (es) 2019-06-06 2022-01-07 Basf Se N-(prid-3-il)carboxamidas fungicidas
WO2021063735A1 (fr) 2019-10-02 2021-04-08 Basf Se Nouveaux dérivés pyridines bicycliques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038325A1 (fr) * 1999-11-10 2001-05-31 Takeda Chemical Industries, Ltd. Composes heterocycliques n a 5 elements a activite hypoglycemique et hypolipidemique
US20100016368A1 (en) * 2008-07-15 2010-01-21 Li Chen Aminotetrahydroindazoloacetic acids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4828914B1 (fr) * 1969-04-11 1973-09-05
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
BE759032A (fr) * 1969-11-17 1971-04-30 Takeda Chemical Industries Ltd Acide 3,5-diphenyl-4-pyrazole acetique ou ses derives 1-substitues ou leurs esters
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
JP2002348281A (ja) * 2001-03-23 2002-12-04 Takeda Chem Ind Ltd ５員複素環アルカン酸誘導体
JP2003073377A (ja) * 2001-06-20 2003-03-12 Takeda Chem Ind Ltd ５員複素環誘導体
MXPA04002855A (es) * 2001-09-25 2004-07-05 Pharmacia Corp Proceso para producir pirazoles sustituidos.
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1471057B1 (fr) 2003-04-25 2006-01-18 Actimis Pharmaceuticals, Inc. Derivés de l'acid pyrimidinylacétique pour le traitment des maladies associées au CRTH2
DE602004011966T2 (de) 2003-10-24 2009-02-12 Glaxo Group Ltd., Greenford Heterocyclylverbindungen
GB0525141D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
US20090149524A1 (en) 2006-06-06 2009-06-11 Paul John Beswick N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration
JP2010526793A (ja) 2007-05-10 2010-08-05 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのピラゾール誘導体
SI2205569T1 (sl) * 2007-09-25 2012-06-29 Actimis Pharmaceuticals Inc Alkiltio pirimidini kot crth2 antagonisti
US8314116B2 (en) 2007-09-25 2012-11-20 Actimis Pharmaceuticals, Inc. 2-S-benzyl substituted pyrimidines as CRTH2 antagonists
GB0719521D0 (en) * 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
WO2009137338A1 (fr) * 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Composés de pyrazole comme antagonistes de ccr1
BR112012018695A2 (pt) 2010-01-27 2016-04-12 Boehringer Ingelheim Int compostos pirazol como antagonistas crth2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038325A1 (fr) * 1999-11-10 2001-05-31 Takeda Chemical Industries, Ltd. Composes heterocycliques n a 5 elements a activite hypoglycemique et hypolipidemique
US20100016368A1 (en) * 2008-07-15 2010-01-21 Li Chen Aminotetrahydroindazoloacetic acids

Also Published As

Publication number Publication date
MX353000B (es) 2017-12-15
UA110025C2 (xx) 2015-11-10
US8791272B2 (en) 2014-07-29
EP2528901B1 (fr) 2015-05-27
PL2528901T3 (pl) 2015-11-30
CL2012001836A1 (es) 2012-11-23
EA022280B1 (ru) 2015-12-30
CY1116641T1 (el) 2017-03-15
TN2012000371A1 (en) 2014-01-30
HK1176062A1 (zh) 2013-07-19
EP2528901B9 (fr) 2017-01-25
IL220208A0 (en) 2012-07-31
AU2011209286A1 (en) 2012-07-05
UY33201A (es) 2011-08-31
MA33937B1 (fr) 2013-01-02
CN104829535A (zh) 2015-08-12
BR112012018695A2 (pt) 2016-04-12
KR20120117841A (ko) 2012-10-24
PT2528901E (pt) 2015-10-13
MY160036A (en) 2017-02-15
DK2528901T3 (en) 2015-08-17
AU2011209286B2 (en) 2016-02-11
ES2545865T3 (es) 2015-09-16
HUE025318T2 (en) 2016-02-29
KR101812000B1 (ko) 2017-12-26
CO6511272A2 (es) 2012-08-31
CN102884051B (zh) 2015-09-16
RS54176B1 (en) 2015-12-31
NZ600637A (en) 2014-07-25
ZA201204335B (en) 2019-08-28
HRP20150898T1 (hr) 2015-10-09
PE20121519A1 (es) 2012-12-02
CN108383789A (zh) 2018-08-10
US20120028938A1 (en) 2012-02-02
TW201138769A (en) 2011-11-16
KR20170142217A (ko) 2017-12-27
MX2012008361A (es) 2012-08-08
JP2013518074A (ja) 2013-05-20
CN102884051A (zh) 2013-01-16
WO2011092140A1 (fr) 2011-08-04
IL220208A (en) 2016-11-30
GEP20146177B (en) 2014-10-10
AR080032A1 (es) 2012-03-07
SI2528901T1 (sl) 2015-10-30
CA2788224A1 (fr) 2011-08-04
EP2528901A1 (fr) 2012-12-05
EA201201050A1 (ru) 2013-02-28
KR101906791B1 (ko) 2018-10-11
CA2788224C (fr) 2015-07-21
SG182684A1 (en) 2012-08-30
TWI499416B (zh) 2015-09-11
AP2012006313A0 (en) 2012-06-30
JP5658284B2 (ja) 2015-01-21

Similar Documents

Publication Publication Date Title
AP3360A (en) Pyrazole compounds as CRTH2 antagonists
HRP20181788T1 (hr) Supstituirani spojevi piridinon-piridinil
EP2627178A4 (fr) Composés de type quinazolinone convenant comme antagonistes de crth2
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
IL225770A0 (en) Heterocyclic compounds
IL221442A0 (en) Heterocyclic compound
ZA201300950B (en) Heterocyclic compound
ZA201304282B (en) Pyrazole derivative
HK1175171A1 (en) Compounds as bradykinin b1 antagonists b1
HK1186183A1 (en) Pyrazole compounds as crth2 antagonists crth2
HK1180971A1 (zh) 吡唑化合物
GB201021416D0 (en) Novel heterocyclic compounds
GB201009514D0 (en) Novel heterocyclic compounds
HK1200443A1 (en) Compounds as bradykinin b1 antagonists b1